| Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade PJ Johnson, S Berhane, C Kagebayashi, S Satomura, M Teng, ... Journal of Clinical Oncology 33 (6), 550, 2015 | 2249 | 2015 |
| Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study AX Zhu, DV Sahani, DG Duda, E di Tomaso, M Ancukiewicz, OA Catalano, ... Journal of clinical oncology 27 (18), 3027, 2009 | 549 | 2009 |
| Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors JA Chan, K Stuart, CC Earle, JW Clark, P Bhargava, R Miksad, ... Journal of Clinical Oncology 30 (24), 2963, 2012 | 309 | 2012 |
| cHCC‐CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation E Brunt, S Aishima, PA Clavien, K Fowler, Z Goodman, G Gores, A Gouw, ... Hepatology 68 (1), 113-126, 2018 | 305 | 2018 |
| Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer A Mahadevan, S Jain, M Goldstein, R Miksad, D Pleskow, M Sawhney, ... International Journal of Radiation Oncology* Biology* Physics 78 (3), 735-742, 2010 | 253 | 2010 |
| Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer A Mahadevan, R Miksad, M Goldstein, R Sullivan, A Bullock, ... International Journal of Radiation Oncology* Biology* Physics 81 (4), e615-e622, 2011 | 248 | 2011 |
| Phase 1/2 study of everolimus in advanced hepatocellular carcinoma AX Zhu, TA Abrams, R Miksad, LS Blaszkowsky, JA Meyerhardt, H Zheng, ... Cancer 117 (22), 5094-5102, 2011 | 240 | 2011 |
| Quality of life implications of bisphosphonate‐associated osteonecrosis of the jaw RA Miksad, KC Lai, TB Dodson, SB Woo, NS Treister, O Akinyemi, ... The oncologist 16 (1), 121-132, 2011 | 207 | 2011 |
| Harnessing the power of real‐world evidence (RWE): a checklist to ensure regulatory‐grade data quality RA Miksad, AP Abernethy Clinical Pharmacology & Therapeutics 103 (2), 202-205, 2018 | 191 | 2018 |
| Effect of high-dose vs standard-dose vitamin D3 supplementation on progression-free survival among patients with advanced or metastatic colorectal cancer: the SUNSHINE … K Ng, HS Nimeiri, NJ McCleary, TA Abrams, MB Yurgelun, JM Cleary, ... Jama 321 (14), 1370-1379, 2019 | 182 | 2019 |
| Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma ZR Qian, DA Rubinson, JA Nowak, V Morales-Oyarvide, RF Dunne, ... JAMA oncology 4 (3), e173420-e173420, 2018 | 182 | 2018 |
| Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis R Miao, H Luo, H Zhou, G Li, D Bu, X Yang, X Zhao, H Zhang, S Liu, ... Journal of hepatology 61 (4), 840-849, 2014 | 155 | 2014 |
| Clinical cancer advances 2017: annual report on progress against cancer from the American Society of Clinical Oncology HJ Burstein, L Krilov, JB Aragon-Ching, NN Baxter, EG Chiorean, ... Journal of Clinical Oncology 35 (12), 1341-1367, 2017 | 148 | 2017 |
| Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting … SD Griffith, M Tucker, B Bowser, G Calkins, C Chang, E Guardino, ... Advances in therapy 36, 2122-2136, 2019 | 132 | 2019 |
| Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer S Khozin, RA Miksad, J Adami, M Boyd, NR Brown, A Gossai, I Kaganman, ... Cancer 125 (22), 4019-4032, 2019 | 115 | 2019 |
| Hepatocellular carcinoma with portal vein tumor involvement: best management strategies PH Liu, TI Huo, RA Miksad Seminars in liver disease 38 (03), 242-251, 2018 | 113 | 2018 |
| Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma A Mahadevan, N Dagoglu, J Mancias, K Raven, K Khwaja, JF Tseng, ... Journal of Cancer 6 (11), 1099, 2015 | 113 | 2015 |
| Progression-free survival as a surrogate endpoint in advanced breast cancer RA Miksad, V Zietemann, R Gothe, R Schwarzer, A Conrads-Frank, ... International journal of technology assessment in health care 24 (4), 371-383, 2008 | 102 | 2008 |
| Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? M RA J Clin Oncol 25, 4506-4507, 2007 | 99 | 2007 |
| An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non–small-cell lung cancer M Stewart, AD Norden, N Dreyer, HJ Henk, AP Abernethy, E Chrischilles, ... JCO clinical cancer informatics 3, 1-15, 2019 | 98 | 2019 |
Dan G. Duda, DMD, PhDProfessor of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School在 partners.org 的电子邮件经过验证
